Some new Yescarta data | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11886 of 12024  at  6/12/2019 8:45:47 AM  by

captsolo


 In response to msg 11885 by  mymorningsong
view thread

Re: Some new Yescarta data

Well, I'm not wrong, and I don't think JUNO will get FDA approval. Changing the names of their drug doesn't fool the FDA. Their drug and trials are not successful in my opinion.

KITE is the commercial leader, has ironed out the CRS issues, and being first in the market means there is no need for an inferior JUNO CAR T - that is not as good (CR) and effective. FDA should not approve JUNO.

What ever happened to JUNO's CAR T? Back in Nov. 2014 JCAR015 received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Here's Celgene's latest report on their CAR T from June 8, 2019. It doesn't appear to me that there has been any great advancement. https://www.marketwatch.com/press-release/united-states-celgene-announces-data-from-ongoing-studies-of-liso
-cel-in-patients-with-difficult-to-treat-blood-cancers-at-asco-2019-2019-06-08


Note JUNO's MRD is only 75%. How do they expect to get FDA approval with an MRD of 75%? KITE's YESCARTA has 100% MRD.

You must think the FDA is blind to all this?


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 277
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...